You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Details for Patent: 10,376,470

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,376,470 protect, and when does it expire?

Patent 10,376,470 protects ROSZET and is included in one NDA.

This patent has eleven patent family members in ten countries.

Summary for Patent: 10,376,470

Title:	Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
Abstract:	Solid dosage formulations containing a combination of rosuvastatin and ezetimibe, as well as methods of making such solid dosage forms and method of treating patients with fixed combination solid dosage forms of rosuvastatin and ezetimibe are provided here.
Inventor(s):	Dias; Marie Charmaine (Morristown, NJ), Ramani; Chandir (Brapton, CA)
Assignee:	Althera Life Sciences, LLC (Morristown, NJ)
Application Number:	15/687,492
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 10,376,470

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Althera Pharms	ROSZET	ezetimibe; rosuvastatin calcium	TABLET;ORAL	213072-001	Mar 23, 2021		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			TREATMENT OF HYPERLIPIDEMIA	⤷ Sign Up
Althera Pharms	ROSZET	ezetimibe; rosuvastatin calcium	TABLET;ORAL	213072-002	Mar 23, 2021		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			TREATMENT OF HYPERLIPIDEMIA	⤷ Sign Up
Althera Pharms	ROSZET	ezetimibe; rosuvastatin calcium	TABLET;ORAL	213072-003	Mar 23, 2021		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			TREATMENT OF HYPERLIPIDEMIA	⤷ Sign Up
Althera Pharms	ROSZET	ezetimibe; rosuvastatin calcium	TABLET;ORAL	213072-004	Mar 23, 2021		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			TREATMENT OF HYPERLIPIDEMIA	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 10,376,470

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Cyprus	1123091	⤷ Sign Up
Denmark	2844233	⤷ Sign Up
European Patent Office	2844233	⤷ Sign Up
Spain	2802252	⤷ Sign Up
Hungary	E052300	⤷ Sign Up
Mexico	2014013241	⤷ Sign Up
Mexico	365046	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.